Navigation Links
Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
Date:5/10/2010

GREENWOOD VILLAGE, Colo., May 10 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced the appointment of Michael Macaluso as Chairman of the Board of Directors. Mr. Macaluso replaces Dr. David Bar-Or, who remains the Chief Scientific Officer and a member of the Board of the Directors. Both Mr. Macaluso and Dr. Bar-Or have served on Ampio's Board since the date of its acquisition of DMI Life Sciences on March 2, 2010.

"Even though Ampio is not yet exchange-listed, the Board recognized that appointing an independent director as Chairman was an important step in strengthening Ampio's governance and internal processes," said CEO Don Wingerter. "We are extremely fortunate to have two directors of the caliber and background of Mike Macaluso and David Bar-Or. Mike's appointment will facilitate David's continued focus on his activities as Chief Scientific Officer and a director, while Mike will bring to the Chairman's role his vision and extensive experience in management, strategic execution, and growth by acquisition." As a founder of and lead investor in Ampio, Mike has had a very successful career ranging from professional player with the MBA to serial entrepreneur and business leader/investor.

The following executive changes were also announced and will be effective May 6, 2010. Bruce G. Miller has been named the Chief Financial Officer of Ampio, and will resign as Ampio's Chief Operating Officer. Mr. Miller continues to serve as the president and chief operating officer of DMI Life Sciences, a wholly-owned subsidiary of Ampio.

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs, some of which we expect will shortly start clinical trials, and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near-term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Investor Contact: Redwood Consultants, LLC at 415-884-0348


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated ... Institute. For Betsy, the clinical trial has been life-saving as she has been ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and ... out for each of his children. “The Angel” is the creation of published author, ... New York City, and impassioned writer. , When asked of her new book, Marjorie ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas in ... where she works in a daycare and looks for inspiration in the local coffee ... Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
Breaking Medicine News(10 mins):